Isofol Medical
ISIN: SE0009581051 | Ticker: ISOFOL | LEI: 549300MCXYAHG7VBHX75
Country: Sweden
Isofol Medical AB (publ), founded in 2008, is a biotech company that is developing a new drug candidate for the treatment of advanced colorectal cancer.
Colorectal cancer (CRC) is the third most common form of cancer worldwide and there is a very high need for more effective drugs to treat this disease.
Vision:
“Isofol will help extend life and improve the quality of life for cancer patients”
Arfolitixorin is being developed and commercialized through a global licensing agreement with Merck & Cie in Germany. The licensing agreement also grants Isofol access to the unique patented manufacturing process for arfolitixorin.
2008
HeadquartersArvid Wallgrens Backe 20, 41346 Gothenburg – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 148,130,000.00 | 401,363,000.00 | 213,464,000.00 |
| Noncurrent Assets | N/A | 8,289,000.00 | 6,755,000.00 | 4,013,000.00 |
| Property Plant And Equipment | N/A | 3,258,000.00 | 1,745,000.00 | 4,013,000.00 |
| Other Property Plant And Equipment | N/A | N/A | 1,745,000.00 | 4,013,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 0.00 | 0.00 | 0.00 |
| Other Noncurrent Financial Assets | N/A | 5,031,000.00 | 5,009,000.00 | 0.00 |
| Current Assets | N/A | 139,841,000.00 | 394,609,000.00 | 209,451,000.00 |
| Trade And Other Current Receivables | N/A | 2,318,000.00 | 0.00 | 0.00 |
| Current Prepaid Expenses | N/A | 12,390,000.00 | 2,884,000.00 | 1,215,000.00 |
| Cash and cash equivalents | 126,983,000.00 | 116,393,000.00 | 379,448,000.00 | 190,583,000.00 |
| Equity And Liabilities | N/A | 148,130,000.00 | 401,363,000.00 | 213,464,000.00 |
| Equity | 104,908,000.00 | 66,567,000.00 | 318,233,000.00 | 158,479,000.00 |
| Issued Capital | N/A | 2,552,000.00 | 4,945,000.00 | 4,945,000.00 |
| Retained Earnings | N/A | -515,077,000.00 | -704,069,000.00 | -904,319,000.00 |
| Additional Paidin Capital | N/A | 768,083,000.00 | 1,217,607,000.00 | 1,217,607,000.00 |
| Liabilities | N/A | 81,563,000.00 | 83,130,000.00 | 54,985,000.00 |
| Noncurrent Liabilities | N/A | 1,439,000.00 | 110,000.00 | 3,250,000.00 |
| Current Liabilities | N/A | 80,124,000.00 | 83,020,000.00 | 51,735,000.00 |
| Trade And Other Current Payables | N/A | 20,889,000.00 | 17,736,000.00 | 7,520,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 37,119,000.00 | 22,407,000.00 | 12,797,000.00 |
| Other Income | 18,000.00 | 0.00 | 59,000.00 |
| Employee Benefits Expense | 22,740,000.00 | 27,721,000.00 | 34,748,000.00 |
| Depreciation And Amortisation Expense | 1,770,000.00 | 1,596,000.00 | 1,642,000.00 |
| Other Expense By Nature | 199,535,000.00 | 196,712,000.00 | 142,114,000.00 |
| Other Gains Losses | 413,000.00 | -843,000.00 | -1,812,000.00 |
| Profit Loss From Operating Activities | -186,494,000.00 | -204,465,000.00 | -167,460,000.00 |
| Finance Income | 4,000.00 | 4,383,000.00 | 7,750,000.00 |
| Finance Costs | 2,501,000.00 | 168,000.00 | 44,000.00 |
| Profit Loss Before Tax | -188,991,000.00 | -200,251,000.00 | -159,755,000.00 |
| Income Tax Expense Continuing Operations | 1,000.00 | 0.00 | 0.00 |
| Profit (loss) | -188,992,000.00 | -200,251,000.00 | -159,755,000.00 |
| Profit Loss Attributable To Owners Of Parent | -188,992,000.00 | -200,251,000.00 | -159,755,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -188,992,000.00 | -200,251,000.00 | -159,755,000.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | -14,050,000.00 | 9,860,000.00 | -504,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | N/A | 38,813,000.00 | 4,907,000.00 | -31,166,000.00 |
| Other Adjustments For Noncash Items | N/A | 3,958,000.00 | -2,946,000.00 | 450,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 1,000.00 | 0.00 | 0.00 |
| Cash Flows From Used In Operating Activities | N/A | -160,270,000.00 | -188,429,000.00 | -190,975,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 0.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | 0.00 | 0.00 | 0.00 |
| Proceeds From Issuing Shares | N/A | 151,258,000.00 | 451,917,000.00 | 0.00 |
| Proceeds From Issuing Other Equity Instruments | N/A | 308,000.00 | 108,000.00 | 23,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,553,000.00 | 1,548,000.00 | 1,704,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 150,013,000.00 | 450,477,000.00 | -1,681,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -10,257,000.00 | 262,048,000.00 | -192,656,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -334,000.00 | 1,007,000.00 | 3,791,000.00 |
| Cash and cash equivalents | 126,983,000.00 | 116,393,000.00 | 379,448,000.00 | 190,583,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 12.09.22 | AB Windar | Other | Buy | SEK 305,000.00 |
| 09.12.21 | Tony Gustavsson | Other | Sell | SEK 858.00 |
| 09.12.21 | Tony Gustavsson | Other | Sell | SEK 152.79 |
| 14.06.21 | HealthCom GmbH | Other | Buy | SEK 1,493,350.40 |
| 10.06.21 | Gustaf Albèrt | Other | Other | SEK 96,979.20 |
| 23.11.20 | Tony Gustavsson | Other | Buy | SEK 43,487.58 |
| 23.11.20 | Tony Gustavsson | Other | Buy | SEK 29,971.17 |
| 16.11.20 | Sven Eriksson | Other | Sell | SEK 43,487.58 |
| 16.11.20 | Sven Eriksson | Other | Sell | SEK 29,971.17 |
| 05.06.20 | Gustaf Albèrt | Other | Other | SEK 5,397.00 |
SE0009581051
LEI549300MCXYAHG7VBHX75
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.